Volume surge · RDY · Healthcare

Dr. Reddy’s Laboratories Ltd ADR (RDY) draws heavier volume in weekly advance

The healthcare ADR’s move has short-term momentum, but confirmation is mixed with the trend signal still inactive.

Dr. Reddy’s Laboratories Ltd ADR
Latest15.38 USD
1W move15.7%
Volume1.7x
TrendInactive
Weekly market chart for Dr. Reddy’s Laboratories ADR with pharmaceutical manufacturing context.

Market update

What happened

Dr. Reddy’s Laboratories Ltd ADR (RDY) closed the latest week at $15.38, rising 15.7% over one week. The weekly price path over 52 weeks shows the ADR lifting into late June after a stronger short-term run.

The setup is not fully confirmed. Market Dynamics shows pressure at -0.37, Relative Strength is 1.6, and the intraday screen was weaker with the latest price down 2.9% at $13.985.

Continue your research

Explore RDY across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.

RDY coverage

Evidence context